The gene-editing biotech Prime Medicine went public on Thursday.
From a key patent to an uncertain timeline, here are five takeaways from Prime's filing.
Its goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA.
Prime editing, another version of next-generation gene editing, works like a word processor, "searching for the correct location and replacing or repairing a wide variety of target DNA," the filing said.
Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is Prime's largest shareholder.